Skip to main content
[Preprint]. 2023 Jul 10:2023.07.10.548208. [Version 1] doi: 10.1101/2023.07.10.548208

Extended Data Fig. 10 |. Pharmacologically inhibiting SGK1 in DNAJB1/PRKACA-expressing AML12 cells.

Extended Data Fig. 10 |

a, b, Immunoblots of phospho-ERK1/2 in non-transformed (a) and DNAJB1/PRKACA-expressing (b) AML12 cells. Cells were treated with DMSO or increasing doses of GS-9007 for 24 hours followed by immunoblotting using the indicated antibodies. c, Bar charts showing quantified pERK levels of indicated treatments in non-transformed and DNAJB1/PRKACA-expressing AML12 cells normalized by the ERK intensity (n=4, means and s.e.m). Statistical significance was determined by two-way student’s t-tests: *P < 0.05; **P < 0.005; ***P < 0.001. d, Schematic of a proposed molecular link between DNAJB1/PRKACA activation and ERK phosphorylation through SGK1.